abstract details

The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.

The safety and effectiveness of bone marrow concentrate injection for knee and hip osteoarthritis: a Canadian cohort


Regen Med. 2021 Jun 30. doi: 10.2217/rme-2021-0001. Online ahead of print.

Robert Burnham 1 2 3Ashley Smith 2 4David Hart 5 6

Author Information

1 Central Alberta Pain & Rehabilitation Institute, Lacombe, AB, Canada.

2 Vivo Cura Health, Calgary, AB, Canada.

3 Division of Physical Medicine & Rehabilitation, University of Alberta, Edmonton, AB, Canada.

4 Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Alberta, Canada.

5 Department of Surgery & Faculty of Kinesiology, University of Calgary, Calgary, AB, Canada.

6 Bone and Joint Health Strategic Clinical Network, Alberta Health Services, Edmonton, AB, Canada.


Aim: Describe the safety and effectiveness of intra-articular bone marrow concentrate (BMC) injection to treat knee and/or hip osteoarthritis (OA) in a Canadian cohort. Materials & methods: A total of 112 patients with refractory OA received a single intra-articular injection of BMC into their knee(s) and/or hip(s). Pain, disability and quality of life were prospectively assessed prior to and 3, 6 and 12 months post-injection. Results: Outcome scores were significantly improved at all time points post-BMC injection with maximal improvement observed at 3-6 months. Improvements were unrelated to patient age, sex or radiographic OA severity. The complication rate was <2%. Interpretation: In this Canadian cohort, knee/hip OA treated with a single BMC injection resulted in significant improvements in pain, disability and quality of life and a low complication rate.